JPMorgan Chase & Co. Purchases Shares of 4,033 Rapport Therapeutics (NASDAQ:RAPP)

JPMorgan Chase & Co. purchased a new position in Rapport Therapeutics (NASDAQ:RAPP) in the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 4,033 shares of the company’s stock, valued at approximately $83,000.

Several other institutional investors and hedge funds have also made changes to their positions in the company. FMR LLC grew its stake in shares of Rapport Therapeutics by 10.1% in the third quarter. FMR LLC now owns 5,486,468 shares of the company’s stock worth $112,363,000 after purchasing an additional 503,117 shares in the last quarter. Geode Capital Management LLC acquired a new stake in Rapport Therapeutics in the 3rd quarter valued at approximately $4,133,000. Millennium Management LLC bought a new stake in shares of Rapport Therapeutics in the 2nd quarter worth approximately $2,716,000. The Manufacturers Life Insurance Company bought a new stake in shares of Rapport Therapeutics in the 2nd quarter worth approximately $1,757,000. Finally, Charles Schwab Investment Management Inc. bought a new position in Rapport Therapeutics in the 3rd quarter valued at $1,498,000.

Rapport Therapeutics Price Performance

NASDAQ RAPP opened at $16.60 on Tuesday. Rapport Therapeutics has a 52 week low of $12.09 and a 52 week high of $29.74. The stock has a fifty day moving average of $17.78 and a 200-day moving average of $20.45.

Rapport Therapeutics (NASDAQ:RAPP) last issued its quarterly earnings results on Thursday, November 7th. The company reported ($0.50) EPS for the quarter, beating analysts’ consensus estimates of ($0.57) by $0.07. On average, sell-side analysts anticipate that Rapport Therapeutics will post -3.65 earnings per share for the current fiscal year.

Rapport Therapeutics Company Profile

Rapport Therapeutics Inc is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc is based in BOSTON.